Advances with the Proteomic test and treatment!

The "proteome» comes from the expression «proteins expressed by a genome». It refers to a complete set of proteins expressed and modified by a specific cell, tissue or organ at a given time under certain conditions. The proteome is constantly changing in response to a series of intracellular and extracellular environmental signals, health or disease, the stage of cell development, and the effects of treatments.

Hello, I am Sergio García, Co-founder of Enevia Health, and today I am writing this post with great optimism to tell you some things that I think are of interest related to the Proteomic Test and the Inbiomiter Laboratory.

Dr. Sinforiano J. Posadas, Doctor in Chemistry from the University of Malaga. He has worked as a consultant in biotechnology. In 2019 he founded Inbiomiter, for research and development of new projects in biotechnology and biomedicine.

As many of you know, I have recently completely carried out the test and subsequent proteomic treatment of the researcher Sinforiano Posadas, with the positive result of having achieved some progress in relation to cognitive functioning. These improvements have consisted of a novel ability to categorize things from the same group, (for example (parts of the body, eye, chest, arms, etc.) and a greater vocabulary, with well-constructed and meaningful sentences. My expectations of having achieved more progress with this treatment were greater, I am quite happy in general with what has been achieved, all of us who are in this tough battle against autism know that any improvement gained is a victory. «-these changes in the maturation processes of the brain remain» in the words of the Sinforian himself.

The proteomic test analyzes the vulnerabilities and disorders of the immune system and neuronal plasticity, and the treatment consists of the sublingual administration of monoclonal antibodies at low doses based on the test results.

Almost at the same time, a mother from Castellón reported to me a very interesting audio about the progress made by her 19-year-old daughter with mild autism. These advances consisted of a greater ability to solve everyday problems by herself and without anyone's help. This fighter is undergoing proteomic treatment along with the administration of what is called activating serum of the immune system (also known as autovaccine). Both treatments together have been a great advance for this 19-year-old woman, which we are extremely happy about.

The misnamed autovaccine is nothing more than the treatment of a blood sample by flow cytometry of the immune cells it contains, separating them and culturing separately those of interest based on the personalized proteomic test.

That is, if the proteomic test indicates autoimmunity in the patient, an immunoregulatory serum will be made, if, on the contrary, the proteomic test indicates a depressed immune system, an activating serum will be prepared, etc. Perhaps the highlight of this type of treatment is that it is possible to direct the antibodies towards the areas of inflammation, blocking the alarm signal. Which reminds me a lot of Professor Naviaux's theory of suramin purinergic therapy. Interesting, right?
Lastly, yesterday, after a long telephone conversation with the researcher Sinforiano Posadas, he told me another piece of good news; the development of a new, more specific test for neurodevelopment, based on the following SCIENTIFIC ARTICLE: neurodevelopment, tea and aging. Which means that from Enevia we are very aware of what this scientist from Malaga is developing based on the biomedical approach to ASD.
Sergio Garcia